首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Therapeutic potential of targeting SHP2 in human developmental disorders and cancers
【24h】

Therapeutic potential of targeting SHP2 in human developmental disorders and cancers

机译:靶向SHP2在人发育障碍和癌症中的治疗潜力

获取原文
获取原文并翻译 | 示例
           

摘要

Src homology 2 (SH2)-containing protein tyrosine phosphatase 2 (SHP2), encoded by PTPN11, regulates cell proliferation, differentiation, apoptosis and survival via releasing intramolecular autoinhibition and modulating various signaling pathways, such as mitogen-activated protein kinase (MAPK) pathway. Mutations and aberrant expression of SHP2 are implicated in human developmental disorders, leukemias and several solid tumors. As an oncoprotein in some cancers, SHP2 represents a rational target for inhibitors to interfere. Nevertheless, its tumor suppressive effect has also been uncovered, indicating the context-specificity. Even so, two types of SHP2 inhibitors including targeting catalytic pocket and allosteric sites have been developed associated with resolved cocrystal complexes. Herein, we describe its structure, biological function, deregulation in human diseases and summarize recent advance in development of SHP2 inhibitors, trying to give an insight into the therapeutic potential in future. (C) 2020 Elsevier Masson SAS. All rights reserved.
机译:SRC同源性2(SH2) - 通过PTPN11编码的蛋白质酪氨酸磷酸酶2(SHP2),通过释放分子内自动抑制和调节各种信号通路,例如丝裂剂活化的蛋白激酶(MAPK)途径来调节细胞增殖,分化,凋亡和存活率,例如丝裂原激活的蛋白激酶(MAPK)途径。 SHP2的突变和异常表达涉及人类发育障碍,白血病和几种实体瘤。作为一些癌症中的癌蛋白,SHP2代表了干扰的抑制剂的理性靶标。然而,它的肿瘤抑制效果也被发现,表明上下文特异性。甚至所以,已经开发了两种类型的SHP2抑制剂,包括靶向催化口袋和变构位点与已分辨的COCrystal络合物相关。在此,我们描述了其结构,生物学功能,人类疾病的放松管制,并总结了SHP2抑制剂的开发的最新进程,试图对未来的治疗潜力深入了解。 (c)2020 Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号